VIROLOGICAL AND MOLECULAR SURROGATES OF RESPONSE TO SARS-COV-2 NEUTRALIZING ANTIBODY SOTROVIMAB

Methods involve deployment of a biomarker panel for classifying patients as responders/non-responders to a SARS-CoV-2 therapeutic (e.g., Sotrovimab) and/or classifying patients as at risk or not at risk for severe infectious disease. Using whole transcriptome data, example biomarker panels are deplo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SORIAGA, Leah B, MAHER, Michael Cyrus Riley, TELENTI, Amalio
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Methods involve deployment of a biomarker panel for classifying patients as responders/non-responders to a SARS-CoV-2 therapeutic (e.g., Sotrovimab) and/or classifying patients as at risk or not at risk for severe infectious disease. Using whole transcriptome data, example biomarker panels are deployed to analyze expression values of certain genes. Such biomarker panels outperform quantifiable clinical laboratory markers (e.g., lymphocytes or neutrophil-lymphocyte ratio), thereby indicating systemic immune response, as evidenced by expression values of biomarkers, provide powerful predictive insights.